Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 108

1.

Recent advances in the application of metabolomics to Alzheimer's Disease.

Trushina E, Mielke MM.

Biochim Biophys Acta. 2014 Aug;1842(8):1232-9. doi: 10.1016/j.bbadis.2013.06.014. Epub 2013 Jun 29. Review.

PMID:
23816564
[PubMed - in process]
2.

Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics.

Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC.

PLoS One. 2013 May 20;8(5):e63644. doi: 10.1371/journal.pone.0063644. Print 2013.

PMID:
23700429
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
[PubMed - indexed for MEDLINE]
4.

Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.

Hampel H, Bürger K, Teipel SJ, Bokde AL, Zetterberg H, Blennow K.

Alzheimers Dement. 2008 Jan;4(1):38-48. doi: 10.1016/j.jalz.2007.08.006. Epub 2007 Dec 21. Review.

PMID:
18631949
[PubMed - indexed for MEDLINE]
5.

Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.

Blennow K, Hampel H, Zetterberg H.

Neuropsychopharmacology. 2014 Jan;39(1):189-201. doi: 10.1038/npp.2013.154. Epub 2013 Jun 25.

PMID:
23799530
[PubMed - in process]
6.

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K.

Exp Neurol. 2010 Jun;223(2):334-46. doi: 10.1016/j.expneurol.2009.09.024. Epub 2009 Oct 6. Review.

PMID:
19815015
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Alterations in metabolic pathways and networks in Alzheimer's disease.

Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, Oki NO, Motsinger-Reif AA, Churchill E, Lei Z, Appleby D, Kling MA, Trojanowski JQ, Doraiswamy PM, Arnold SE; Pharmacometabolomics Research Network.

Transl Psychiatry. 2013 Apr 9;3:e244. doi: 10.1038/tp.2013.18.

PMID:
23571809
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.

Kang JH, Vanderstichele H, Trojanowski JQ, Shaw LM.

Methods. 2012 Apr;56(4):484-93. doi: 10.1016/j.ymeth.2012.03.023. Epub 2012 Apr 6. Review.

PMID:
22503777
[PubMed - indexed for MEDLINE]
9.

Cerebrospinal fluid biomarkers for Alzheimer's disease.

Blennow K, Zetterberg H.

J Alzheimers Dis. 2009;18(2):413-7. doi: 10.3233/JAD-2009-1177. Review.

PMID:
19661632
[PubMed - indexed for MEDLINE]
10.

Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease.

Oh ES, Troncoso JC, Fangmark Tucker SM.

Neuromolecular Med. 2008;10(3):195-207. doi: 10.1007/s12017-008-8035-0. Epub 2008 Jun 10. Review.

PMID:
18543125
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Alzheimer's disease beyond the genomic era: nuclear magnetic resonance (NMR) spectroscopy-based metabolomics.

Barba I, Fernandez-Montesinos R, Garcia-Dorado D, Pozo D.

J Cell Mol Med. 2008 Sep-Oct;12(5A):1477-85. doi: 10.1111/j.1582-4934.2008.00385.x. Epub 2008 Jun 28. Review.

PMID:
18554316
[PubMed - indexed for MEDLINE]
12.

New developments in mild cognitive impairment and Alzheimer's disease.

Schott JM, Kennedy J, Fox NC.

Curr Opin Neurol. 2006 Dec;19(6):552-8. Review.

PMID:
17102693
[PubMed - indexed for MEDLINE]
13.

Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity.

Hampel H, Mitchell A, Blennow K, Frank RA, Brettschneider S, Weller L, Möller HJ.

J Neural Transm. 2004 Mar;111(3):247-72. Epub 2003 Dec 3. Review.

PMID:
14991453
[PubMed - indexed for MEDLINE]
14.

Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.

Lista S, Zetterberg H, Dubois B, Blennow K, Hampel H.

J Neurol. 2014 Jun;261(6):1234-43. doi: 10.1007/s00415-014-7366-z. Epub 2014 May 8.

PMID:
24807087
[PubMed - in process]
15.

Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development.

Nordberg A.

Alzheimers Res Ther. 2011 Dec 2;3(6):34. doi: 10.1186/alzrt96.

PMID:
22136152
[PubMed]
Free PMC Article
16.

Vaccines for Alzheimer's disease: how close are we?

Janus C.

CNS Drugs. 2003;17(7):457-74. Review.

PMID:
12751917
[PubMed - indexed for MEDLINE]
17.

Targeting norepinephrine in mild cognitive impairment and Alzheimer's disease.

Chalermpalanupap T, Kinkead B, Hu WT, Kummer MP, Hammerschmidt T, Heneka MT, Weinshenker D, Levey AI.

Alzheimers Res Ther. 2013 Apr 29;5(2):21. doi: 10.1186/alzrt175. eCollection 2013. Review.

PMID:
23634965
[PubMed]
Free PMC Article
19.

Fluid biomarkers in Alzheimer's disease - current concepts.

Rosén C, Hansson O, Blennow K, Zetterberg H.

Mol Neurodegener. 2013 Jun 21;8:20. doi: 10.1186/1750-1326-8-20. Review.

PMID:
23800368
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease.

de la Monte SM.

Drugs. 2012 Jan 1;72(1):49-66. doi: 10.2165/11597760-000000000-00000. Review.

PMID:
22191795
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk